Retatrutide has become one of the most talked-about names in metabolic medicine, and for good reason. In clinical trials it has produced weight loss numbers that exceed every currently approved option. It is also a perfect example of how the line between GLP-1 drugs and peptides has blurred.
This guide explains what retatrutide is, its weight loss results and side effects, how it compares to Ozempic and Mounjaro, and the important fact that it is not yet available. We will keep the focus on evidence, not hype.
What Is Retatrutide?
Retatrutide is an investigational, once-weekly injectable medication developed by Eli Lilly for obesity and weight management. The word investigational is important: it is still in development and not yet approved.
It is also a peptide. Like semaglutide and tirzepatide, retatrutide is a peptide-based incretin medication, which is why it sits right at the intersection of the GLP-1 and peptide worlds we describe in our GLP-1 vs peptides guide. If you want the basics on what that means, our overview of what peptides are is a good starting point.
How Retatrutide Works: The Triple-Agonist Mechanism
What sets retatrutide apart is that it activates three different receptors at once. This is why it is called a triple hormone receptor agonist.
It targets the GLP-1 receptor, which reduces appetite and slows digestion. It targets the GIP receptor, which supports insulin sensitivity and metabolism. And it adds a third target, the glucagon receptor, which plays a role in energy expenditure and fat metabolism.
Current approved drugs hit one or two of these targets. By engaging all three, retatrutide appears to amplify the metabolic effect, which is the leading explanation for its larger weight loss in trials.
Retatrutide Weight Loss Results
The numbers are what put retatrutide on the map, and they come from two stages of trials.
In the phase 2 trial published in the New England Journal of Medicine, the highest 12-mg dose produced an average weight reduction of 24.2% at 48 weeks, compared with about 2.1% for placebo. Eli Lilly’s own summary confirmed these phase 2 figures.
The larger phase 3 TRIUMPH-1 trial went further. As reported by AJMC, the highest dose produced roughly 28.3% average body weight reduction over 80 weeks in a study of more than 2,300 adults, with a large share of participants losing 30% or more.
To put that in perspective, those results exceed the weight loss seen with current approved GLP-1 medications.
How Retatrutide Compares to Ozempic and Mounjaro
It helps to line up the three generations of incretin medications by how many receptors they target.
| Medication | Active peptide | Receptors targeted | Trial weight loss |
|---|---|---|---|
| Ozempic / Wegovy | Semaglutide | GLP-1 | Up to ~15% |
| Mounjaro / Zepbound | Tirzepatide | GIP + GLP-1 | Up to ~20-22% |
| Retatrutide (investigational) | Retatrutide | GIP + GLP-1 + glucagon | Up to ~28% (phase 3) |
The trend is clear: each added receptor target has been associated with greater average weight loss. For a deeper look at the current approved options, see our Ozempic vs Mounjaro comparison. The crucial difference is availability, which we turn to next.
Is Retatrutide Available Yet?
No, and this is the most important practical point. As of mid-2026, retatrutide is investigational and not FDA approved. It is not available through legitimate prescription channels.
That creates a serious caution. Because demand is high and the drug is not yet on the market, products claiming to be retatrutide have appeared in the research-chemical and gray market. These are unapproved and unverified, with no assurance of what the vial actually contains, how pure it is, or how it is dosed. Buying and using them carries real and avoidable risk.
If your current treatment has stalled, the safer path is to work with your provider on approved options. Our guide on what to do when Ozempic is not working covers evidence-based steps rather than unapproved substitutes.
Retatrutide Side Effects
In trials, retatrutide’s side effect profile looked similar to other incretin-based therapies. The most common effects were gastrointestinal, including nausea, vomiting, and diarrhea.
These were generally mild to moderate and occurred most often during the dose-escalation phase, the same pattern seen with semaglutide and tirzepatide. Long-term safety is still being studied as the phase 3 program continues.
The Bottom Line
Retatrutide is the most striking sign yet that GLP-1 drugs and peptides are one continuous landscape, not two separate things. It is a peptide, a triple-agonist medication, and the current trial leader in weight loss, with up to about 28% reduction in phase 3.
But it is not approved and not legitimately available yet, and anything sold under its name today should be treated as an unverified gray-market product. To understand where retatrutide fits among approved options, read our GLP-1 vs peptides and Ozempic vs Mounjaro guides, and make any treatment decision with a qualified healthcare provider.